De-risking measures limit COVID-19 damage to GIC portfolio
Singapore’s GIC Private said that steps taken last year to de-risk its portfolio – reducing its allocation to equities in favor of cash and evaluating deals with more caution – have limited the negative impact of COVID-19.
Further, the sovereign wealth fund, which claims to have invested well over $100 billion while independent assessments put its wealth at more than $300 billion, expects its long-term outlook to pay off...
More on Southeast Asia
Latest News
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
PE investors agree $5.7b 51job take-private
A consortium led by DCP Capital Partners has finalized terms for a $5.7 billion privatization of US-listed Chinese online recruitment platform 51job.
Chinese drug developer Abbisko files for HK IPO
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.